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Abstract: 
Background: Outside of pregnancy, closed-loop insulin delivery can 
improve glycemic control, but safety, efficacy and feasibility in pregnancy 
have not been established.  
Methods: An open-label, randomized, crossover study comparing overnight 
closed-loop with sensor-augmented pump therapy, followed by a day-and-
night closed-loop continuation phase. 16 participants completed four weeks 
of closed-loop (intervention) and sensor-augmented pump therapy 
(control) in random order. During the feasibility phase, 14 participants 
continued day-and-night closed-loop until delivery. The primary end point 
was the proportion of time with glucose level within target (63-140mg/dL).  
Results: The proportion of time with overnight glucose level within target 
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was higher during closed-loop than control (74.7% vs 59.5%; absolute 
difference 15.2 percentage points, CI95%=6.1 to 24.2; p=0.002). The 
overnight mean glucose was lower during closed-loop (absolute difference 
14mg/dL, CI95% = -23 to -4mg/dL; p=0.009). Overnight time spent 
hypoglycemic (1.9% vs 1.3%; p=0.28), insulin dose and adverse event 
rates did not differ between study phases. During the continuation phase, 
14 women used day-and-night closed-loop (for up to an additional 14.4 
weeks), including during acute antenatal hospital admissions and delivery. 
They continued to maintain safe glycemic control with 67.6-77.3% time in 
target and mean glucose levels of 115-128mg/dL.  Near-optimal glucose 
control was achieved (86.8% time in target and mean glucose 110mg/dL) 
before delivery. There were no episodes of severe hypoglycemia requiring 
third-party assistance.  
Conclusions: Overnight closed-loop was associated with better glucose 
control than sensor-augmented pump therapy in pregnant women with 
type 1 diabetes. Day-and-night closed-loop safely maintained glycemic 
control during antenatal hospital admissions, labor and delivery.  
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Background: Outside of pregnancy, closed-loop insulin delivery can improve glycemic control, but 
safety, efficacy and feasibility in pregnancy have not been established.  
Methods: An open-label, randomized, crossover study comparing overnight closed-loop with sensor-
augmented pump therapy, followed by a day-and-night closed-loop continuation phase. 16 
participants completed four weeks of closed-loop (intervention) and sensor-augmented pump 
therapy (control) in random order. During the feasibility phase, 14 participants continued day-and-
night closed-loop until delivery. The primary end point was the proportion of time with glucose level 
within target (63-140mg/dL).  
Results: The proportion of time with overnight glucose level within target was higher during closed-
loop than control (74.7% vs 59.5%; absolute difference 15.2 percentage points, CI95%=6.1 to 24.2; 
p=0.002). The overnight mean glucose was lower during closed-loop (absolute difference 14mg/dL, 
CI95% = -23 to -4mg/dL; p=0.009). Overnight time spent hypoglycemic (1.9% vs 1.3%; p=0.28), insulin 
dose and adverse event rates did not differ between study phases. During the continuation phase, 
14 women used day-and-night closed-loop (for up to an additional 14.4 weeks), including during 
acute antenatal hospital admissions and delivery. They continued to maintain safe glycemic control 
with 67.6-77.3% time in target and mean glucose levels of 115-128mg/dL.  Near-optimal glucose 
control was achieved (86.8% time in target and mean glucose 110mg/dL) before delivery. There 
were no episodes of severe hypoglycemia requiring third-party assistance.  
Conclusions: Overnight closed-loop was associated with better glucose control than sensor-
augmented pump therapy in pregnant women with type 1 diabetes. Day-and-night closed-loop 
safely maintained glycemic control during antenatal hospital admissions, labor and delivery.  
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Introduction 
Maternal and infant complications of type 1 diabetes in pregnancy include higher rates of congenital 
anomaly, stillbirth, neonatal death, preterm delivery, and macrosomia (1). Congenital anomalies are 
associated with peri-conception glycemic control while the remaining complications are associated 
with maternal hyperglycemia which persists during pregnancy (2–5).  
 
However, women with type 1 diabetes face a number of particular challenges in trying to maintain 
optimal glycemic control throughout pregnancy. Physiological and pharmacological factors mean 
that insulin doses increase two-to threefold during the second and third trimesters, with substantial 
day-to-day variability, making insulin dose adjustment unpredictable (6,7). Even with regular glucose 
monitoring, intensive insulin therapy and “safe” HbA1c levels, pregnant women with type 1 diabetes 
spend an average of 50% time (12 hours per day) with glucose levels outside the recommended 
range (8,9). They also have increased rates of hypoglycemia (6,10–12), spending up to 15% time (3.5 
hours per day) below target (8), so the benefit of avoiding hyperglycemia for the infant must be 
weighed against the risk of hypoglycemia for the mother.  
 
Technological advances in glucose monitoring and insulin delivery, including continuous glucose 
monitoring (CGM), insulin pumps and the combination of pump therapy with continuous glucose 
monitoring, known as sensor-augmented pump therapy may facilitate safer improvements in 
glycemic control. However effectiveness of these technologies in pregnancy is not established (13).  
 
Closed-loop systems use a computer algorithm (set of mathematical instructions) to adjust insulin 
pump delivery in response to glucose measurements obtained via real-time continuous glucose 
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monitors (14). , Closed-loop systems can improve glycemic control without increasing hypoglycemia 
under experimental (15–17), supervised outpatient (18–22), and free-living conditions (23–25). 
Preliminary data suggest that closed-loop may be able to maintain near-normal glucose levels and 
prevent nocturnal hypoglycemia in pregnant women with type 1 diabetes (26,27). Here we present a 
four week randomized crossover study of overnight closed-loop, followed by a 14 week feasibility 
phase of day-and-night closed-loop, which incorporates particular gestational challenges, including 
antenatal hospital admissions, labor, delivery and postnatal adaptation. We hypothesized that 
extended use of closed-loop would be safe, effective and feasible during pregnancy.  
 
Methods 
Study participants 
We recruited pregnant women who had had type 1 diabetes for a minimum of 12 months. 
Participants were between eight and 24 weeks gestation, had a booking HbA1c between 48 and 
86mmol/mol (6.5-10%) and were aged 18-45 years. They were receiving intensive insulin therapy via 
either multiple daily injections or an insulin pump. Exclusion criteria included conception using 
assisted reproductive technologies, concurrent treatment that may influence glucose control, 
significant vascular complications and multiple pregnancy.  
Study oversight 
The study protocol was approved by the Health Research Authority, East of England Regional Ethics 
Committee   (13/EE/0018), with notification of no objection provided by the Medicines and 
Healthcare Products Regulatory Agency, UK (CI/2013/0036). The trials are on the International 
Standard Randomised Controlled Trial Number register (ISRCTN71510001).  
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All participants provided written informed consent and the study was overseen by an independent 
data and safety monitoring board.  
 
Abbott Diabetes Care provided discounted continuous glucose monitoring devices and consumables. 
They played no role in study design; collection, handling, analysis, or interpretation of data; the 
decision to publish. The National Institute for Health research (NIHR) and Abbott Diabetes Care 
reviewed the manuscript prior to submission but did not suggest any changes to the manuscript and 
did not play a role in manuscript preparation or revision. Two authors hold patents related to closed-
loop and insulin delivery systems that use measurement-error models.  
 
Study design 
The study was an open-label, multicenter, randomized, crossover trial. Participants were recruited 
from three UK National Health Service (NHS) maternity sites.  
 
After enrolment, participants were trained to use the study devices; a Dana Insulin Pump and an 
Abbott Navigator Continuous Glucose Monitor. After a two to four week run-in period for device 
training and optimization of insulin doses, participants were allocated using permuted 4-block 
randomization to either sensor-augmented pump therapy (control phase) or overnight closed-loop 
(intervention phase). After completing four weeks of the allocated intervention, participants had a 
two week washout before completing the alternate study phase. During the washout phase, 
participants used finger-stick testing with or without continuous glucose monitoring or pump 
therapy, but could not use closed-loop.  
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After completion of the randomized interventions, the continuation phase allowed participants to 
choose to continue either sensor augmented pump therapy or day-and-night closed-loop with 
manual meal boluses until delivery. This provided a longer-term feasibility assessment of 24-hour 
closed-loop while accommodating the ethical considerations of pregnancy.  
  
Finger-stick glucose testing was recommended at least seven times daily with standard glucose 
targets in both groups (pre-meal 63-99mg/dL and one-hour post meal <140mg/dL). Participants had 
routine antenatal clinic visits every two weeks with fetal ultrasound assessments at 12, 20, 28, 32 
and 36 weeks gestation. There were no restrictions on physical activity, meals or overseas travel and 
no remote monitoring. Participants had access to a 24-hour phone line for assistance with technical 
difficulties. 
 
 
C-peptide was measured during euglycemia at baseline, and glycated hemoglobin was measured at 
baseline, after each intervention arm, and at 28, 32, and 36 weeks gestation. A flow chart 
demonstrating the study design is available in the supplementary files.  
 
 
Closed-loop in pregnancy system 
During closed-loop, a computer program, housed on a tablet computer, used CGM glucose 
measurements to determine an appropriate dose of insulin every 12 minutes, which was then 
delivered via an insulin pump (see Figure 2). Pre-meal boluses were given manually (15-30 minutes 
before eating) as clinically indicated (28). To initialize closed-loop, the participant’s weight and total 
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daily dose of insulin with usual basal rates were entered. During the four week randomized phase, 
participants were instructed to initiate closed-loop after their evening meal and to discontinue it 
before breakfast. During the day-and-night closed-loop feasibility phase, it was continued over the 
entire 24 hours. In order to maintain connectivity of the devices, the CGM receiver and tablet 
computer had to be within approximately 30 meters of the participant while closed-loop was 
operational.  There was no announcement of antenatal steroids, labor or delivery to the system. 
Carbohydrate-to-insulin ratios were changed as soon as possible after delivery and prandial insulin 
was withheld for the first meal post-delivery. 
 
Study end points 
The primary efficacy endpoint was the percentage of time that glucose was in the target range of 63-
140mg/dL overnight, as recorded by CGM during each four week study phase. Secondary efficacy 
outcomes were mean sensor glucose, percentage of overnight and day and night time with glucose 
levels above and below relevant thresholds, glucose variability, insulin dose and glycated 
hemoglobin (see supplementary files).  
 
Safety was evaluated by examining the number of episodes of hypoglycemia (moderate and severe), 
and the duration and outcome of those events. Moderate hypoglycemia was defined as CGM 
glucose levels <63mg/dL for ≥20minutes. A severe hypoglycemia episode was one requiring third 
party assistance. 
 
 
Page 8 of 62
Confidential:  Destroy when review is complete.
Submitted to the New England Journal of Medicine
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential:  For Review
8 
 
Feasibility was assessed during the day-and-night closed-loop continuation phase from the end of 
the crossover study periods until delivery.  
 
Sample size 
Our preliminary in-patient closed-loop study participants (median HbA1c 47 mmol/mol or 6.4%) 
using sensor augmented pump therapy spent 61.7 (24.9) % time-in-target (27). To detect a 30% 
relative increase (from 62% to 80% time-in-target), we estimated that 16 participants were needed 
to achieve 80% power and an alpha level of 0.05 (two-tailed). The standard deviation of the primary 
outcome was assumed to be 25% as previously observed (26,27). 
 
Statistical analysis 
Statistical analyses were performed on an intention-to-treat basis, with data analyzed according to 
the study phase to which the participant was allocated, regardless of compliance. Results between 
sensor-augmented pump therapy and closed-loop were compared using linear mixed effects models, 
with the response variable being overnight time-in-target; the study arm as a fixed effect; and study 
participant and 4-week block within participant as nested random effects. Functional data analyses 
of the CGM data (29) were performed and adjusted for gestation, period effect and period by study 
arm interaction. Sequential glucose measurements were modelled as trajectories by calculating 
continuous mathematical functions of glucose measurements. These trajectories were modeled 
using the technique of fitting B-splines to the repeated measures (30). A two-sided significance level 
of 0.05 is used for both primary and secondary outcomes, without accounting for multiplicity. 
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Results 
Study participants 
Twenty participants were recruited to the study. Of these, three withdrew during the run-in training 
phase and 17 participants were randomized. One participant withdrew during her first study phase 
(sensor-augmented pump therapy) because of termination of pregnancy for trisomy 13 (a 
chromosomal anomaly unrelated to diabetes). Sixteen participants completed both study arms and 
are included in analyses (see Table 1). Six participants were using multiple daily insulin injections, 
and 14 participants were continuous glucose monitoring naïve prior to the study. 14 participants had 
baseline C-peptide measurements of less than 33pmol/L, with two participants who had levels of 64 
and 119pmol/L.  
 
Endpoints 
There was a 15 percentage point improvement in the percent of overnight time participants spent 
with glucose values within the target range during closed-loop compared to sensor-augmented 
pump therapy (absolute difference 15.2 percentage points, CI95%=6.1 to 24.2; p=0.002; Figure 1, 
Table 2). The mean glucose was significantly lower during closed-loop, both overnight (absolute 
difference 14mg/dL, CI95%=-23 to -4mg/dL; p=0.009; Table 2) and across 24 hours (128 vs 137 mg/dL, 
p<0.0001; see Tables 2 and 3).  
 
There was reduced maternal hyperglycemia during closed-loop therapy both overnight and across 
24 hours. Most striking, was the reduction in substantial nocturnal hyperglycemia (glucose levels 
>180mg/dL), which was approximately halved during overnight closed-loop compared to sensor-
augmented pump therapy (Table 2). Functional data analysis demonstrated that overnight closed-
Page 10 of 62
Confidential:  Destroy when review is complete.
Submitted to the New England Journal of Medicine
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential:  For Review
10 
 
loop was associated with a significantly lower glucose for a total time of 7 hours and 20 minutes 
(between 01.50-09.20hrs) with no impact of gestation and no period effect (see supplementary 
files).  
 
Time spent hypoglycaemic (<63mg/dL) was very low (<2%) with no difference between the two 
study phases. There were no episodes of severe hypoglycaemia requiring third-party assistance 
during either study phase.  
 
With regards to glycated hemoglobin, there was a reduction from baseline to the end of both the 
sensor-augmented pump and closed-loop phases (p=0.02 and p=0.003 respectively). There was no 
difference between the study periods (p=0.67). Participants used similar total daily doses of insulin 
across both study phases, although as expected insulin delivery was significantly more variable 
during closed-loop (p<0.0001 see supplementary files). 
 
Adverse events 
There were 26 adverse events (14 skin reactions, 12 minor illnesses), with no difference between 
sensor-augmented pump and closed-loop study phases.  There were 95 device deficiencies (47 CGM 
device and connectivity, 21 insulin pump, 14 downloading devices, 13 closed-loop tablet). There 
were eight serious adverse events; one hospital admission following an episode of self-treated 
hypoglycemia (following recurrent vomiting) occurred during the overnight closed-loop study phase 
but in the daytime when closed-loop was not operational. Another (vomiting due to gastroenteritis) 
occurred during the run-in training phase and six occurred during the feasibility phase (see 
supplementary files). No serious adverse events were device-related.  
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Feasibility of day and night closed-loop throughout pregnancy 
Fourteen participants chose to continue using closed-loop after finishing the crossover studies 
providing up to an additional 14.4 weeks of day and night closed-loop use for feasibility assessment. 
Participants maintained a median glucose of 124, 128, 124, 115mg/dL at 24-28, 28-32, 32-36, and 
>36 weeks gestation respectively (see supplementary files). Median time spent with target glucose 
levels was 70.9, 67.6, 67.8, and 77.3% at 24-28, 28-32, 32-36, and >36 weeks gestation. The median 
time spent hypoglycemic was 1.2-2.1% throughout pregnancy. 
 
Closed-loop during labor and delivery 
Fourteen women continued closed-loop insulin delivery during labor and delivery (see 
supplementary files). In the 24 hours before delivery, participants using closed-loop had a mean 
glucose of 110 (104, 128)mg/dL, spent 86.8 (59.6, 94.1)% time-in- target (63-140mg/dL) and 0.5 (0, 
1.8)% time below 63mg/dL; median (interquartile range). In the first 48 hours post-partum, 
participants had a mean glucose of 117 (104, 137)mg/dL, spent 73.7 (61.4, 86.0)% time-in-target and 
0 (0, 0.5)% time below 63mg/dL; median (interquartile range). Total daily insulin doses were 53.6 
(48.6, 73.6) percent of the pre-delivery dose; median (interquartile range) with substantial inter-
individual variability; see supplementary files. There were no episodes of maternal hypoglycaemia 
during the 24 hours prior to or 48 hours post-delivery. 
 
Obstetric and neonatal outcomes 
Median (interquartile range) gestation at delivery was 36.9 weeks (34.5, 37.7 weeks). Five 
participants developed pre-eclampsia, including one with hemolysis, elevated liver enzyme and low 
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platelets (HELLP) syndrome. Fifteen women delivered via cesarean section (two under general 
anesthesia), with ten performed prior to onset of labor. One participant required an ovarian 
cystectomy during cesarean section. Seven participants delivered prior to 37 weeks gestation (four 
prior to 34 weeks) and six had antenatal steroids administered for fetal lung maturation. During the 
first 72 hours after steroid administration, participants spent a median of 58.1-70.9 percent of the 
time with glucose levels between 63 and 140mg/dL.  Closed-loop delivered a median of 169-178% of 
the pre-steroid total daily insulin dose although there was substantial inter-individual variability; see 
supplementary files. Median (interquartile range) birthweight was 3587.5g (2670, 3997.5g). Thirteen 
of the 16 infants had a sex and gestational age-corrected birthweight above the 90
th
 centile using a 
population-based UK reference (31). Twelve infants were admitted to neonatal intensive care, 
eleven of which were treated with intravenous dextrose for neonatal hypoglycemia. Individual 
obstetric outcomes are available in the supplementary files.  
 
Discussion 
Overnight closed-loop was associated with a 15% percentage point increase in the time spent within 
the glucose target range for pregnancy compared with sensor-augmented pump therapy, and a 
reduction in mean glucose of 14mg/dL, corresponding to a reduction in glycated hemoglobin of 
5.5mmol/mol or 0.5% (32). These improvements were achieved without increased hypoglycemia or 
total insulin dose, but with more variable insulin delivery targeted to minimize hyperglycemic 
excursions. Despite the closed-loop system only being used overnight, improvements persisted 
across the entire 24 hours.  
 
Day-and-night closed-loop was continued by 14 participants for up to an additional 14 weeks, 
demonstrating the feasibility of 24-hour use of closed-loop during pregnancy and in the immediate 
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48 hours post-partum. This is important because pregnancy provides formidable challenges to 
closed-loop, including week-by-week changes in insulin resistance and pharmacokinetics (26), acute 
antenatal admissions, administration of steroids for fetal lung maturation, general or regional 
anesthesia for cesarean section, labor and delivery, and the rapid decrease in insulin requirements 
post-partum. Such a diverse array of challenges has not been assessed in previous outpatient closed-
loop studies (18,23), which focused on relatively steady-state diabetes, outside of pregnancy. Here, 
we demonstrate that the built-in adaptability of the closed-loop system could safely maintain 
maternal glycemic control throughout pregnancy, delivery, and immediately post-partum, without 
any announcement of these events to the system.   
 
The randomized crossover design reduced the impact of confounding factors. There was no period 
or gestation effect, suggesting that closed-loop adjusted insulin consistently. No prior closed-loop 
studies have included participants using multiple daily insulin injections. We included 14 sensor 
naïve and six pump naïve participants. We found that their glycemic control outcomes were 
comparable to experienced users. The multi-center design and use during acute antenatal hospital 
admissions further suggests feasibility in real-world scenarios.  
 
Our findings build on recent trials demonstrating that closed-loop is associated with improved 
glycemic control, without increased hypoglycemia or insulin dose (18,23). Strikingly, the glucose 
control achieved during our control phase is comparable to that achieved by closed-loop 
interventions involving non-pregnant participants, reflecting the unique motivation of pregnancy. 
Despite impressive glycemic control with sensor-augmented pump therapy, closed-loop still 
generated substantial improvements when used overnight. Day-and-night closed-loop with pre-meal 
boluses safely maintained glycemic control, with our participants spending about 20 percent more 
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time-in-target than our previous continuous glucose monitoring cohorts without closed-loop (8). 
Such glycemic control improvements would be expected to lead to improved pregnancy outcomes 
but larger clinical trials are necessary to assess obstetric and neonatal outcomes.  
 
Our sample size is small but includes women with long duration of diabetes and substantial obstetric 
morbidity including five miscarriages, one late gestation termination, two early preterm deliveries 
and two stillbirths. This perhaps contributes to the unexpectedly high neonatal morbidity.  
 
In conclusion, we found that overnight and day-and-night closed-loop is safe and feasible for women 
with type 1 diabetes in pregnancy, in free-living home and in-patient hospital environments, 
including during labor and delivery. Overnight closed-loop was associated with improved glucose 
control without increased hypoglycemia or insulin doses.  
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Baseline characteristics (N=16) Number Mean (SD) 
 
Age (years) 
 
34.1 (4.6) 
BMI (kg/m
2
)  29.7 (5.7) 
HbA1c (mmol/mol/%)  50.8 (6.2)/6.8(0.6)  
Duration of diabetes (years)  23.6 (7.2) 
Pump use prior to study 10 
 CGM use prior to study 2 
Total daily insulin dose (units)  52.8 (18.1) 
Weeks gestation*  14 (3.3) 
Primiparous± 7 
 Recruitment site 
- Cambridge 
- Norwich 
- Ipswich 
 
10 
5 
1  
*Weeks gestation at randomization. Randomization was performed after recruitment and 2-4 weeks 
of device training when insulin regimens were optimized and participants were competent using the 
study devices. 
±Among the nine women with previous pregnancies, there were five with previous pregnancy losses 
(five miscarriages and two stillbirths), one with late gestation termination of pregnancy for major 
malformationand two early preterm deliveries (before 34 weeks). 
Table 1: Baseline characteristics of study participants 
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 Sensor-augmented 
pump therapy 
Closed-loop Absolute 
difference (CI95%) 
P value 
Overnight (2300hrs-0700hrs) 
Time in target  
(%; 63-140mg/dL) 
59.5 74.7 15.2 (6.1 to 24.2) 0.002 
Time above target 
(%; >140mg/dL) 
38.6 24.0 -14.5 (-24.2 to -4.9) 0.005 
Time in substantial 
hyperglycaemia 
(%, >180mg/dL) 
15.7 7.4 -8.3 (-13.7 to -3.0) 0.004 
Time below target  
(%; <63mg/dL) 
1.9 1.3 -0.6 (-1.7 to 0.6) 0.28 
Time in moderate hypoglycaemia 
(%; <50mg/dL) 
0.6 0.3 -0.2 (-0.9 to -0.4) 0.45 
Number of hypoglycaemic events 
(Median [range];  
<63mg/dL for≥20 minutes) 
2.5 (0-15) 3 (0-6)  0.68 
Low blood glucose index 1.3 1.3 0.1 (-0.4 to 0.5) 0.78 
Mean glucose   
(mg/dL) 
133 119 -14 (-23 to -4) 0.009 
Area under the curve: 
(median [interquartile range]) 
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- glucose >140mg/dL  
- glucose >121mg/dL 
- glucose <63mg/dL 
- glucose <50mg/dL 
147.7 (40.2-322.4) 
383.8 (222.0-608.9) 
0 
0 
39.2 (9.9-142.2) 
169.6 (98.5-413.7) 
0 
0 
 0.07 
0.04 
Standard deviation of sensor 
glucose 
(mg/dL) 
27 25 -2 (-4 to 0) 0.13 
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Table 2: Comparison of sensor-augmented pump therapy and closed-loop automated insulin 
delivery during the overnight period (2300-0700hrs) for the crossover phases of the study. The 
values reported are derived from linear mixed effects models. 
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 Sensor-
augmented pump 
therapy 
Closed-loop Absolute 
difference (CI95%) 
P value 
Day and night during crossover phase 
Time in target 
(%; 63-140mg/dL) 
56.8 66.3 9.4 (5.1 to 13.8) 
 
<0.001 
Time above target 
(%; >140) 
40.9 31.6 -9.4 (-13.7 to -5.0) 
 
<0.001 
Time in substantial 
hyperglycaemia 
(%, >180mg/dL) 
17.3 12.6 -4.7 (-7.3 to -2.1) 0.001 
Time below target 
(%; <63 mg/dL) 
1.8 1.9 0.1 (-0.3 to 0.5) 0.67 
Time in moderate 
hypoglycaemia 
(%; <50mg/dL) 
0.33 0.39 0.05 (-0.1 to 0.2) 0.52 
Number of hypoglycaemic 
events  
(Median [range];  
<63mg/dL for ≥20 minutes) 
12 (2-26) 11 (0-37)  0.19 
Mean glucose  
(mg/dL) 
137 128 -9 (-14 to -4) <0.001 
TDD insulin (units/day) 58.2 59.8 1.7 (-6.9-10.2) 0.67 
Sensor wear (hours) 20.6 21.1 0.5 (-1.0-2.0) 0.47 
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Table 3: Comparison of sensor-augmented pump therapy and closed-loop automated insulin 
delivery during the day-and-night during the crossover phase of the study. It should be noted that 
the closed-loop system was only active overnight during this phase of the study and that pre-meal 
boluses were given manually (15-30 minutes before eating) as clinically indicated. The values 
reported are derived from linear mixed effects models.
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Figure 1: Median sensor glucose values and interquartile ranges over 24hrs in sensor-augmented 
pump therapy and closed-loop interventions. Sensor-augmented pump therapy phase shaded in 
grey, overnight closed-loop phase shaded in red. Functional data analyses further confirmed 
statistically significant differences in glucose control for a total time of 7 hours and 20 minutes (from 
0150hrs to 0920hrs) with no impact of gestation and no period effect.  
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Continuous 
glucose monitor 
Tablet computer 
Insulin pump 
 
 
 
 
 
 
 
 
 
 
  
Figure 2: The closed-loop system. An individually-adaptive control algorithm is housed on a tablet 
computer and uses glucose readings from the continuous glucose monitor to adjust insulin delivery via the 
insulin pump every 12 minutes when closed-loop is turned on. Pre-meal boluses are given manually (15-30 
minutes before eating), using the bolus adviser on the insulin pump. 
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Supplementary files 
Supplementary figure 1: Flow of participants through the study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
‡
All participants choose to continue the study continuous glucose monitoring and insulin pump 
devices during the washout. 
 
Washout Phase (2-4 weeks)‡ 
Continue pump therapy with or 
without CGM 
Study pump+ CGM with 
overnight Closed-loop 
28 nights 
Flow of participants through the study 
Study Pump + CGM without 
 Closed-loop  
28 nights 
Recruitment & informed consent 
 
2-4 week run-in device training period 
Baseline HbA1c and C peptide measurement 
Randomization 
End of Crossover study HbA1c 
 
Feasibility continuation phase 
Participants can choose to continue with either the study pump 
and CGM (sensor augmented pump therapy) or day and night 
closed-loop until up to 48 hours after delivery. 
 
Post Intervention HbA1c Post Intervention HbA1c 
Study Pump and CGM without  
Closed-loop 
28 nights 
Study pump+ CGM with overnight 
Closed-loop 
28 nights 
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Supplementary figure 2: Consort flow diagram  
 
  
33 assessed for eligibility 
13 excluded 
• 7 did not meet 
inclusion/exclusion criteria 
• 4 declined participation 
• 2 participants in another trial 
20 consented and trained 
on study pump and CGM 
17 randomized 
8 assigned to sensor-
augmented pump therapy 
9 assigned to sensor-
augmented pump therapy 
with overnight closed-loop 
9 assigned to sensor-
augmented pump therapy 
7 assigned to sensor-
augmented pump therapy 
with overnight closed-loop 
16 completed and analyzed 
as per intention to treat 
14 continued using day and 
night closed-loop & were 
included in feasibility phase 
assessments 
3 dropped out during run-in training 
phase. 1 moving out of area, 1 mental 
health issue, 1 disliked study pump 
1 drop out‡ 
‡ Drop-out as a result of chromosomal anomaly (trisomy 13) unrelated to 
diabetes and subsequent termination of pregnancy.  
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Supplementary figure 3: Glycemic control during labor and delivery in participants using closed-
loop with manual pre-meal boluses 
  
Participants 5, 6, 8, 9, and 15 received antenatal glucocorticoids for fetal lung maturation. 
Participant 3 had a severe urinary tract infection in the antepartum period, which was the reason for 
her delivery. Participant 15 has primary adrenal insufficiency (Addison’s disease) and was treated 
with high dose glucocorticoid in the immediate post-partum period. 
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Supplementary table 1: Glycemic control during the randomised crossover study in participants 
who were using Multiple Daily Injections (MDI) vs insulin pump therapy at enrollment 
  
 Previous MDI users (n=6) Previous Pump users (n=10) 
 Sensor-
augmented 
pump 
Closed-
loop 
Difference 
(CL-SAP) 
Sensor-
augmented 
pump 
Closed-
loop 
Difference 
(CL-SAP) 
% Time in target (63-
140mg/dL) overnight 
 
66.0 78.8 15.8 58.3 73.8 16.9 
Mean glucose 
overnight (mg/dL) 
 
126 117 9 133 119 -14 
Median number of 
episodes of nocturnal 
hypoglycemia 
(63mg/dL for ≥20 
mins) 
3.5 2.5 -1 3 2 -1 
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Supplementary table 2: Insulin doses during the sensor-augmented pump therapy and overnight 
closed-loop randomised crossover study 
 
 Sensor-augmented 
pump therapy 
Closed-loop p-value 
Overnight (2300-
0700hrs) 
   
Total daily dose 
(units/night) 
 
10.5 10.2 0.79 
Basal (units/night) 9.0 9.4 0.63 
 
Bolus (units/night) 1.6 0.9 0.05 
 
Standard deviation of 
basal insulin (units) 
 
0.2 0.8 <0.0001 
Day and night    
Total daily dose 
(units/24hrs) 
 
61.5 58.5 0.46 
Basal (units/24hrs) 
 
28.1 28.8 0.88 
Bolus (units/24hrs)‡ 33.2 31.2 0.58 
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Standard deviation of 
basal insulin (units) 
0.2 0.7 <0.0001 
‡ Pre-meal boluses were given manually (15-30 minutes before eating) as clinically indicated. 
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Supplementary Table 3: Day and night glucose measurements during the 24-hour closed-loop 
continuation phase, from completion of the crossover interventions until delivery; median 
(interquartile range) 
  
 24-28 weeks 
gestation 
(n = 14) 
28-32 weeks 
gestation 
(n = 12) 
32-36 weeks 
gestation 
(n = 13) 
36+ weeks 
gestation 
(n = 9) 
Percentage time 
in target 
(63-140mg/dL) 
 
70.9 (63.8, 76.5) 67.6 (62.2, 73.7) 67.8 (66.0, 79.4) 77.3 (72.4, 83.6) 
Percentage time 
above target 
(>140mg/dL) 
27.7 (22.4, 35.7) 30.8 (25.7, 35.7) 30.6 (19.2, 31.4) 20.7 (16.4, 25.4) 
Percentage time 
below target  
(<63mg/dL) 
 
1.2 (0.4, 1.8) 1.2 (0.5, 1.6) 1.5 (0.8, 2.1) 2.1 (0.5, 2.4) 
Mean glucose 
(mg/dL) 
 
124 (119, 131) 128 (122, 133) 124 (117, 128) 115 (117, 119) 
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Supplementary table 4: Glycemic control measures by participant during the sensor augmented pump (SAP) and overnight closed-loop randomised 
crossover studies and during ongoing day and night closed-loop use with advancing gestation until delivery 
 
Participant 
number 
Measure SAP study arm Closed-loop  
arm 
24-28 weeks 28-32 weeks 32-36 weeks 36 weeks+ 
1 % time in target (63-140mg/dL) 46.4 44.7 44.2 54.3 55 69.8 
 % time >140mg/dL 52.3 55.2 55.5 45.2 43.3 27.9 
 % time <63mg/dL 1.2 0.0 0.3 0.5 1.7 2.3 
 Mean glucose (mg/dL) 149 157 157 148 140 128 
 HbA1c (mmol/mol / %)  52/6.9  53/7.0   
2 % time in target (63-140mg/dL) 58.5 70.3 76.4  67.6 84.9 
 % time >140mg/dL 39.7 27.9 23.1  31.4 13.0 
 % time <63mg/dL 1.8 1.8 0.4  0.9 2.1 
 Mean glucose (mg/dL) 131 122 121  128 110 
 HbA1c (mmol/mol / %) 48/6.5 50/6.7 48/6.5 49/6.6 52/6.9  
3 % time in target (63-140mg/dL) 46.7 59.1 61.0 54.9 64.1  
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 % time >140mg/dL 52.9 50.5 38.5 45.1 35.8  
 % time <63mg/dL 0.4 0.4 0.5 0 0.1  
 Mean glucose (mg/dL) 144 135 135 140 133  
 HbA1c (mmol/mol / %) 52/6.9 54/7.1 54/7.1 56/7.3   
4† % time in target (63-140mg/dL) 36.0 58.6 71.2 71.1 76.2 77.3 
 % time >140mg/dL 63.8 40.9 28.8 28.6 23.0 22.6 
 % time <63mg/dL 0.2 0.5 0 0.3 0.8 0.1 
 Mean glucose (mg/dL) 160 137 126 126 121 119 
 HbA1c (mmol/mol / %) 43/6.1 38/5.6 41/5.9 43/6.1 44/6.2  
5*† % time in target (63-140mg/dL) 69.1 68.7     
 % time >140mg/dL 29.3 29.1     
 % time <63mg/dL 1.6 2.3     
 Mean glucose (mg/dL) 124 124     
 HbA1c (mmol/mol / %) 40/5.8 43/6.1 40/5.8    
6† % time in target (63-140mg/dL) 64.3 75.9 77.3 65.9 66.0 68.4 
 % time >140mg/dL 32.0 21.0 20.1 32.0 30.6 25.4 
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 % time <63mg/dL 3.7 3.1 2.6 2.0 3.4 6.2 
 Mean glucose (mg/dL) 124 117 113 130 124 115 
 HbA1c (mmol/mol / %) 43/6.1 40/5.8     
7 % time in target (63-140mg/dL) 52.5 71.3 62.9  80.8  
 % time >140mg/dL 44.8 28.1 36.8  19.2  
 % time <63mg/dL 0.5 0.5 0.3  0  
 Mean glucose (mg/dL) 144 126 131  117  
 HbA1c (mmol/mol / %) 50/6.7 49/6.6 53/7.0 52/6.9   
8† % time in target (63-140mg/dL) 52.9 62.3 70.7 80.3 72.1  
 % time >140mg/dL 44.8 35.3 27.9 18.3 25.4  
 % time <63mg/dL 2.3 2.3 1.5 1.5 2.5  
 Mean glucose (mg/dL) 142 130 124 115 119  
 HbA1c (mmol/mol / %) 59/7.5 50/6.7 48/6.5 47/6.5   
9ꭞ % time in target (63-140mg/dL) 62.5 69.9 81.1 71.5   
 % time >140mg/dL 34.4 26.4 17.0 28.0   
 % time <63mg/dL 3.1 3.7 2.0 0.4   
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 Mean glucose (mg/dL) 128 121 10 122   
 HbA1c (mmol/mol / %) 34/5.4 45/6.3 34/5.4    
10† % time in target (63-140mg/dL) 76.3 93.7 77.6 83.2 86.6 92.9 
 % time >140mg/dL 20.5 13.8 19.3 15.9 11.4 3.9 
 % time <63mg/dL 3.1 2.5 3.1 0.9 2.1 3.2 
 Mean glucose (mg/dL) 115 108 113 113 108 99 
 HbA1c (mmol/mol / %) 38/5.6 44/6.2 37/5.5    
11‡† % time in target (63-140mg/dL) 54.1 57.2 66.4 67.4 67.0 77.1 
 % time >140mg/dL 44.1 41.6 32.2 30.1 31.0 20.5 
 % time <63mg/dL 1.7 1.2 1.4 2.5 1.9 2.4 
 Mean glucose (mg/dL) 139 140 128 126 124 115 
 HbA1c (mmol/mol / %) 43/6.1 49/6.6 45/6.3  44/6.2  
12‡ % time in target (63-140mg/dL) 46.3 46.9 55.5 58.9 67.8 78.8 
 % time >140mg/dL 51.7 51.6 43.3 39.5 30.7 20.7 
 % time <63mg/dL 2.0 1.5 1.1 1.6 1.5 0.5 
 Mean glucose (mg/dL) 148 148 139 137 126 117 
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 HbA1c (mmol/mol / %) 53/7.0 54/7.1 54/7.1 53/7.0 52/6.9  
13 % time in target (63-140mg/dL) 74.3 67.7 69.9 63.3 79.4 72.4 
 % time >140mg/dL 23.3 29.0 27.6 34.4 17.9 25.5 
 % time <63mg/dL 2.5 3.3 2.5 2.2 2.7 2.1 
 Mean glucose (mg/dL) 119 122 122 133 113 122 
 HbA1c (mmol/mol / %) 45/6.3 47/6.5 47/6.5 49/6.6 48/6.5  
14* % time in target (63-140mg/dL) 77.4 78.7     
 % time >140mg/dL 21.1 18.3     
 % time <63mg/dL 1.6 3.1     
 Mean glucose (mg/dL) 115 112     
 HbA1c (mmol/mol / %) 38/5.6 40/5.8 34/5.3 36/5.4 35/5.4  
15ꭞ % time in target (63-140mg/dL) 41.6 70.6 73.2 68.7 56.8  
 % time >140mg/dL 56.9 28.3 25.9 29.6 42.0  
 % time <63mg/dL 1.5 1.1 0.9 1.7 1.2  
 Mean glucose (mg/dL) 155 124 122 126 140  
 HbA1c (mmol/mol / %) 53/7.0 47/6.5 48/6.5 51/6.8   
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16 % time in target (63-140mg/dL) 56.8 75.3 76.5 80.3 82.4 83.6 
 % time >140mg/dL 41.8 22.8 22.2 18.7 17.4 16.4 
 % time <63mg/dL 1.3 1.9 1.3 1.0 0.2 0.1 
 Mean glucose (mg/dL) 137 117 119 117 117 115 
 HbA1c (mmol/mol / %) 45/6.3 45/6.3 47/6.5  46/6.4  
*Participants 5 and 14 used sensor-augmented pump therapy without closed-loop after the crossover phase  
‡ Par^cipants 11 and 12 had euglycaemic c-peptide results of 64 and 119 pmol/L respectively.  
† Par^cipants 4, 5, 6, 8, 10, and 11, were pump-naïve prior to enrollment in the study 
ꭞ Participants 9 and 15 had used CGM prior to the study. All other participants were CGM-naïve  
Page 43 of 62
Confidential:  Destroy when review is complete.
Submitted to the New England Journal of Medicine
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential:  For Review
43 
 
Supplementary table 5: Glucose control (mean glucose and percentage time in target 63-
140mg/dl) and insulin doses after administration of antenatal steroids; median (interquartile 
range) 
 
 
 Average over 7 
days prior to 
steroid 
administration 
0-24 hours post 
1
st
 steroid dose 
24-48 hours post 
1
st
 steroid dose 
48-72 hours post 
1
st
 steroid dose 
Time in target % 73.0 (69.6, 79.4) 58.1 (48.3, 66.9) 59.1 (53.8, 70.8) 70.9 (66.0, 77.1) 
Time >140 mg/dL; 
% 
25.0 (20.2, 28.4) 41.8 (29.8, 51.6) 40.9 (24.4, 46.2) 26.5 (20.8, 32.6) 
Time <63 mg/dL; 
% 
2.1 (1.7, 2.3) 0.0 (0, 0.2) 0 (0, 0) 0.5 (0, 2.1) 
Mean glucose; 
mg/dL 
121 (115, 124) 135 (122, 146) 140 (130, 142) 121 (110, 131) 
Total daily dose of 
insulin; units 
40.7 (36.1, 59.8) 65.3 (60.0, 75.3) 70.1 (66.8, 83.1) 78.9 (60.1, 96.8) 
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Supplementary table 6: Glucose control (mean glucose and percentage time in target 63-
140mg/dl) prior to and in the first 72 hours after antenatal steroid administration by participant 
Participa
nt 
number 
Measure Average over 7 
days prior to 
steroid 
administration; 
0-24 hours 
post 1st 
steroid dose 
24-48 hours 
post 1st 
steroid dose 
48-72 hours 
post 1st 
steroid dose 
05 Time in target % 85.8 68.7 70.8 74.7 
Mean glucose; 
mg/dL 
110 117 115 110 
06 Time in target % 70.0 36.4 53.8 77.9 
Mean glucose; 
mg/dL 
124 151 142 115 
07 Time in target % 80.6 85.3 76.1 92.6 
Mean glucose; 
mg/dL 
119 121 130 108 
Percentage of pre-
steroid total daily 
dose of insulin; % 
100 169 (111, 234) 176 (155, 224) 178 (103, 248) 
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08‡ Time in target % 69.5 46.2 Closed-loop 
not 
operational 
67.2 
Mean glucose; 
mg/dL 
126 148 126 
09 Time in target % 76.0 61.6 59.1 56.6 
Mean glucose; 
mg/dL 
115 126 140 146 
15 Time in target % 65.0 54.5 16.4 65.6 
Mean glucose; 
mg/dL 
126 144 185 133 
‡ Overnight midwifery and obstetric staﬀ were unfamiliar with the closed-loop system and set up a 
variable rate intravenous insulin infusion which was discontinued and replaced by closed-loop the 
following morning. 
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Supplementary table 7: Insulin doses prior to and in the first 72 hours after antenatal steroid 
administration by participant 
 
Participant 
number 
Average over 7 
days prior to 
steroid 
administration; 
units 
0-24 hours post 
1
st
 steroid dose; 
units (% of pre-
steroid dose) 
24-48 hours post 
1
st
 steroid dose; 
units (% of pre-
steroid dose) 
48-72 hours post 
1
st
 steroid dose; 
units (% of pre-
steroid dose) 
05 34.6 78.0 (226%) 61.0 (176%) 95.6 (277%) 
06 61.9 146.4 (237%) 138.8 (224%) 108.2 (175%) 
07 75.5 67.2 (89%) 66.8 (88%) 59.4 (79%) 
08‡ 40.7 46.1 (113%) Closed-loop not 
operational 
28.7 (70%) 
09 53.4 58.9 (110%) 83.1 (155%) 97.2 (182%) 
15 23.0 63.5 (276%) 70.1 (305%) 62.2 (270%) 
‡ Overnight midwifery and obstetric staﬀ were unfamiliar with the closed-loop system and set up a 
variable rate intravenous insulin infusion which was discontinued and replaced by closed-loop the 
following morning.  
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Supplementary table 8: Total daily doses of insulin in the 24 hours prior to delivery and the first 
two days post-partum for participants using the closed-loop system 
 
Participant 
number 
Total insulin 
dose 24 hours 
prior to delivery 
(units) 
Total insulin dose day 1 
post-partum 
Units (% of pre-delivery 
dose) 
Total insulin dose for day 2 
post-partum 
Units (% of pre-delivery dose) 
1 99.1 50.3 (50.8) 55.2 (55.7) 
2 45.2 33.3 (73.5) 23.8 (52.5) 
3 141.5 70.1 (49.5) 70.6 (49.9) 
4 84.3 55.3 (65.6) 39.5 (46.9) 
5 91.2 48.9 (53.6) 66.7 (73.1) 
6* 51.2 79.5 (155.2) 27.4 (53.5) 
8 No insulin data available 
9 101.3 31.0 (30.6) 30.8 (30.4) 
10 39.4 19.2 (48.6) 23.6 (59.9) 
11 150.9 124.4 (82.5) 84.5 (56.0) 
12 48.8 29.3 (60.0) 37.3 (76.4) 
13 65.0 Participant did not wear closed-loop for the 48 hours 
following delivery 
15‡ 38.4 47.2 (123.0) 54.7 (142.5) 
16 54.5 21.0 (38.6) 17.5 (32.2) 
*Participant 6 had a high total daily insulin dose on day 1 post-partum as a result of high 
carbohydrate intake and accompanying large prandial boluses. On day 2 post-partum she resumed 
her normal dietary intake.  
‡Par^cipant 15 has co-existing primary adrenal insufficiency (Addison’s disease) and was treated 
with 150mg intravenous dexamethasone for 48 hours post-partum. When her data are excluded the 
median % of pre-delivery insulin dose on day 1 post-partum is 53.6 (48.6, 73.5) and on day 2 post-
partum 53.5 (46.9, 59.9). 
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Functional data analysis 
 
We used functional data analysis (29) to evaluate temporal trends in CGM data between the 
interventions. Functional data analysis allows extraction of shape information and identification of 
patterns (or ‘signals’) that are not identified by more commonly used summary statistical measures 
when analyzing complex data from frequent sampling. It allows interrogation of the trajectories of 
blood glucose levels without oversimplifying the data collected. It yields quantifiable measures (of 
absolute values over time, velocity and acceleration) and allows physiological interpretation of the 
data accounting for their complexity of the temporal character. It can be used to summarize 
temporal trends in continuously recorded measurements in a form that is amenable to subsequent 
multivariable statistical analysis.  The models examined order of intervention and month of 
intervention, separately and together. Multivariable regression established the time points that 
glucose was significantly different using overnight closed-loop compared with sensor-augmented 
pump therapy.  
The graph demonstrates the difference in glucose levels observed throughout the 24-hour day, 
when using overnight closed-loop compared with sensor-augmented pump therapy. It demonstrates 
that overnight closed-loop is associated with a significantly lower glucose from 0150hrs until 
0910hrs (total 7 hours and 20 minutes).  
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Supplementary figure 4: Mean sensor glucose values and 95% confidence intervals over 24hrs in 
sensor-augmented pump therapy (grey) and overnight closed-loop (red) randomized crossover 
phase of study 
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Supplementary table 4: Individual obstetric and neonatal outcomes with details of previous obstetric and medical complications 
Participant 
number 
Gravidity Parity Obstetric 
history 
Medical 
history 
Gestation 
at 
delivery 
Antenatal 
steroids 
Mode of 
delivery 
Birthweight 
of infant (g) 
Neonatal 
hypoglycaemia 
Neonatal 
intensive 
care 
admission 
Obstetric 
complications 
1 4 2 1 miscarriage N/A 37+0 No C-section 3700 Yes, treated 
naso-gastric 
feeds 
 
No N/A 
2 1 0 N/A N/A 38+4 No C-section 3455 No No N/A 
 
3 5 3 1 stillbirth, 1 
miscarriage, 
2 preterm 
deliveries 
<34/40 
Hypertension 34+5 No C-section* 2700 Yes, treated IV 
dextrose 
Yes Intrapartum 
UTI 
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4 3 1 Previous late 
termination 
for major 
malformation 
N/A 37+1 No NVD (IOL) 4020 Yes, treated 
supplemental 
feeds 
 
No 2
nd
 degree 
tear 
5 3 2 2 preterm 
deliveries 
<34/40 
N/A 31+1 Yes C-
section*± 
1382 Yes, treated IV 
dextrose 
Yes Premature 
rupture of 
membranes. 
Post-partum 
haemorrhage 
 
6 1 0 N/A N/A 37+2 Yes C-section 3515 No Yes N/A 
 
7 1 0 N/A N/A 35+1 Yes C-section* 2870 Yes, treated IV 
dextrose 
 
Yes Preeclampsia 
& HELLP 
syndrome. 
8 2 0 1 miscarriage N/A 33+6 Yes C-section* 2520 Yes, treated IV Yes Preeclampsia 
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dextrose  & 
nasogastric feeds 
 
9 3 1 1 stillbirth, 1 
miscarriage 
Rheumatoid 
arthritis, 
Coeliac disease, 
Hypertension, 
Factor V leiden 
thrombophilia 
28+4 Yes C-section* 850 Yes, treated IV 
dextrose 
 
Yes Preeclampsia 
10 1 0 N/A N/A 38+2 No C-section* 4155 Yes, treated IV 
dextrose 
 
Yes - NH Post-partum 
haemorrhage 
11 2 0 1 miscarriage N/A 37+5 No C-section* 4530 Yes, treated IV 
dextrose 
 
Yes N/A 
12 1 0 N/A N/A 37+5 No C-section* 4632 Yes, treated No Preeclampsia 
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supplemental 
feeds 
 
13 2 1 1 livebirth N/A 37+2 No C-section 3825 Yes, treated IV 
dextrose 
 
Yes N/A 
14 1 0 N/A Hypertension 38+5 No C-section 3990 Yes, treated IV 
dextrose 
 
Yes - NH Exacerbation 
of pre-existing 
hypertension 
15 1 0 N/A 4x islet cell 
transplants, 
Addison’s, 
gastroparesis 
33+5 Yes C-section* 2580 Yes, treated IV 
dextrose 
Yes Preeclampsia  
16 3 2 2 livebirths N/A 36+5 No C-
section*+ 
3660 Yes, treated IV 
dextrose 
Yes Placenta 
praevia 
*Caesarean section before onset of labour. The five remaining participants experienced caesarean section after the onset of labour. 
*± Caesarean section under spinal anesthesia followed by ovarian cystectomy under general anesthesia 
+ Caesarean section under general anesthesia
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Supplementary table 5: Details of serious adverse events. Included are details of the in-hospital 
use of day and night closed-loop.  
 
Event 
number 
Study phase Device-
related 
 
Description 
1 Run in No Admitted with 1 day of vomiting - likely gastroenteritis, no 
diabetic ketoacidosis. Good response to anti-emetics. Participant 
withdrew from study prior to randomization due to a change in 
personal circumstances (moving out of area). 
2 Closed-loop 
arm 
No Admitted with hypoglycaemia in the context of persistent 
vomiting diagnosed as viral gastroenteritis. Participant was 
unable to raise her blood glucose sufficiently using oral 
treatments (because of vomiting) and treated herself with 
glucagon before presenting to A&E. She did not require third 
party assistance. She was in the overnight closed-loop study 
phase but was using sensor-augmented pump therapy without 
closed-loop. This event occurred during the daytime hence she 
had not yet turned on the closed-loop system.  
3 Sensor-
augmented 
pump arm 
No Congenital anomaly detected on routine anomaly scan 
(identified as trisomy 13 on subsequent genetic testing). 
Participant was withdrawn from the study and subsequently had 
a termination of pregnancy.  
4 Follow up 
(day & night 
No Admitted for 24 hours to investigate threatened labor (later 
diagnosed as Braxton Hicks contractions). She remained on 
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closed-loop) closed-loop throughout her hospital admission.  
5 Follow up 
(day & night 
closed-loop) 
No Spontaneous rupture of membranes at 30 weeks gestation and 
admitted for antenatal steroids. She continued closed-loop 
during steroid administration, throughout labor and delivery.  
6 Follow up 
(day & night 
closed-loop) 
No Admitted with preeclampsia at 23+5 weeks gestation. She was 
treated with antenatal steroids and continued closed-loop. She 
remained an inpatient until delivery at 28+2 weeks gestation. 
She has rheumatoid arthritis, coeliac disease, hypertension and 
Factor V Leiden thrombophilia. She had not previously had a 
successful pregnancy (previous miscarriage and stillbirth). 
7 Follow up 
(day & night 
closed-loop) 
No Admitted with preeclampsia at 34+4 weeks gestation. She used 
sensor-augmented pump therapy and closed-loop in hospital. 
She was treated with anti-hypertensives and antenatal steroids 
before delivery caesarean-section at 35+1 weeks gestation.  
8 Follow up 
(open label 
closed-loop) 
No Admitted for investigation of hypertension and malaise at 32+3 
weeks gestation. She used both sensor-augmented pump and 
closed-loop in hospital.  
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Methods 
 
Automated closed-loop insulin delivery system 
This study used the FlorenceD2W closed-loop system (University of Cambridge, Cambridge, UK). This 
system comprized a model predictive control algorithm housed on a tablet computer (Dell Latitude 
10 tablet; Dell, TX, USA), which was linked by cable to the continuous glucose monitoring receiver 
(FreeStyle Navigator II, Abbott Diabetes Care, Alameda, CA, USA) and communicated via Bluetooth 
with the study insulin pump (Dana R Diabecare, Sooil, Seoul, South Korea).  
Every 12 minutes the control algorithm calculated an insulin rate which was automatically sent to 
the study insulin pump. The control algorithm calculations used a compartment model of glucose 
kinetics which described the effect of rapid-acting insulin analogues and the carbohydrate content of 
meals on glucose levels. The control algorithm was initialized using pre-programmed basal insulin 
rates downloaded from the study pump, the participant’s weight and their total daily insulin dose. 
The treat-to-target control algorithm aimed to achieve glucose levels between 97 and 124 mg/dL 
and adjusted the actual level depending on fasting versus post-prandial status and the accuracy of 
the model-based glucose predictions. Control algorithm version 0.3.27p was used (University of 
Cambridge, Cambridge UK).  
The continuous glucose monitoring receiver provided hypoglycemia and hyperglycemia alarms, the 
insulin pump provided standard alarms related to insulin delivery issues, and the tablet computer 
provided alarms related to closed-loop function (e.g., start, stop, termination, errors).  
Participants were trained to perform a calibration check before starting closed-loop insulin delivery 
in the evening. If the sensor glucose was above the fingerstick glucose by more than 54 mg/dL, 
participants were advised to recalibrate the continuous glucose monitoring device. If the sensor 
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glucose became unavailable, pre-programmed insulin delivery was automatically restarted within 30 
minutes or within 1 hour in the case of other failures.  
 
Experimental protocol 
After providing informed consent, participants were trained to use the study insulin pump and 
continuous glucose monitor by an experienced pump educator. The study device training sessions 
lasted between 2-4 hours. For participants who had been using an insulin pump prior to enrollment 
in the study, their usual basal rates, carbohydrate ratios, and correction factors were entered into 
the pump. For participants who were pump naïve, their average basal rate from multiple daily 
injections was calculated over the previous three days. Eighty percent of the average total basal 
dose was programmed as a flat basal rate across 24 hours, and their pre-existing carbohydrate ratios 
and correction factors were entered into the pump. The target blood glucose was set at 108mg/dL.  
The participant’s competency using both the study pump and continuous glucose monitor was 
assessed and documented by the pump educator. Participants who were competent using the study 
devices undertook a two to four week run-in period. During this time, their insulin doses were 
titrated as they would be in routine clinical practice by research team clinicians, diabetes educators, 
or the participant’s clinical team. Participants who were new to insulin pump therapy were given the 
same care and training as they would have received had they commenced on an insulin pump in the 
routine clinic setting. All but one pump naïve participant commenced both study devices 
simultaneously, with one participant starting CGM before pump training. At the conclusion of the 
study period, participants’ compliance with the study devices was assessed. Participants who wore 
the continuous glucose monitor for a minimum of 96 hours with at least 24 hours (three nights) of 
glucose values between 11pm and 7am were eligible for randomization.  
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Randomization to the order of study interventions (sensor-augmented pump therapy and sensor-
augmented pump therapy with overnight closed-loop) was performed using web-based 4-block 
randomization. There was no stratification of center or other factors and there was no masking. At 
the randomization visit, blood samples were also taken for glycated hemoglobin, c-peptide, and 
random glucose.  
 
On the first day of the closed-loop study arm, participants were trained to use the tablet computer 
system. Training was provided by the research team at the participant’s home, or at the participant’s 
treating hospital, and included training on starting and stopping closed-loop, responding to alarms, 
and calibrating the system. After the training session, which lasted between 30-60 minutes, 
competency using the closed-loop system was assessed and documented by the study team.  
 
Participants were instructed to start closed-loop insulin delivery after their evening meal and to stop 
it before breakfast the next morning. Participants used the closed-loop system unsupervised at 
home for a total of 28 nights. During the sensor-augmented pump therapy study arm, participants 
used the study pump and continuous glucose monitor without closed-loop. 
 
Throughout both study arms, all participants had access to a 24-hour telephone helpline to contact 
the study team in the event of any technical problems. There were no restrictions in terms of 
exercise, diet, or travel. Standard local advice regarding treatment of hypo- and hyperglycemia was 
followed throughout the study period.  
Participants were reviewed biweekly, at which time their study devices were downloaded. The 
participants also provided downloaded data from their tablet computers every week while they 
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were using closed-loop. Participants had identical planned contacts with the study team during the 
two study arms (weekly phone or email contact and biweekly study visits). At the conclusion of each 
study arm, a blood sample was collected to measure glycated hemoglobin. All glycated hemoglobin 
samples were analyzed centrally at Cambridge, UK.  
During the washout period, participants were free use the study pump and continuous glucose 
monitor if they chose to, but not closed-loop. In the current study all participants continued with 
continuous glucose monitor and insulin pump therapy. 
 
After completion of both intervention arms, participants were able to choose their diabetes 
treatment for the remainder of their pregnancies, including the option to continue using 24-hour 
closed-loop. Participants who chose to continue using the closed-loop system were reviewed every 
two weeks, at which time their study devices were downloaded. HbA1c measurements were 
collected at 28, 32, and 36 weeks gestation. 
 
Participants, in conjunction with their clinical teams, could choose to continue using the closed-loop 
system throughout labor and delivery. They were required to discontinue using the closed-loop 
system prior to discharge from hospital after delivery, or within one week of delivery, whichever was 
sooner.  
Summary of differences between the two intervention arms: 
- Closed-loop training session provided on the first day of the closed-loop study arm 
- Use of overnight closed-loop insulin delivery during the closed-loop study arm 
- Participants were contacted via phone or email after their first night using closed-loop  
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Summary of Study Outcomes: 
• Primary outcome: The primary outcome is the percentage time spent with glucose levels ≥ 
63mg/dl and ≤140mg/dl (3.5 and ≤ 7.8mmol/l), as recorded by continuous glucose 
monitoring (CGM) during the 28 day intervention periods.  
Secondary outcomes: 
• The overnight time with glucose levels in the hypoglycaemic range, based on continuous 
glucose monitoring (glucose levels < 50mg/dl or 2.8mmol/L).  
• The overnight time with glucose levels in the hyperglycaemic range, based on continuous 
glucose monitoring (glucose levels > 140mg/dl or 7.8mmol/L).  
• The overall time (day and night) with glucose levels in the hypoglycaemic range, based on 
continuous glucose monitoring (glucose levels < 50mg/dl or 2.8mmol/l).  
• The overall time (day and night) with glucose levels in the hyperglycaemic range, based on 
continuous subcutaneous glucose monitoring, (glucose levels > 140mg/dl or 7.8mmol/L).  
• Metabolic control assessed by change in HbA1c after the use of closed-loop for 28 days, 
compared with that during sensor augmented pump therapy for 28 days. HbA1c will be 
measured before and after each intervention arm.    
• CGM data collected during intervention arms will also be compared to baseline CGM 
readings. 
• Trends in CGM data collected within intervention arms will also be evaluated on weekly 
basis. 
•  Percentage time spent with CGM < 63mg/dl (3.5mmol/l) to quantify borderline 
hypoglycaemia 
• Percentage time spent with CGM ≤ 50mg/dl (2.8mmol/l) to quantify moderate 
hypoglycaemia 
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• Percentage time spent with CGM > 140mg/dl (7.8mmol/l) to quantify the duration of 
hyperglycaemia 
• Percentage time spent at CGM > 180mg/dl (10.0 mmol/l) to quantify significant 
hyperglycaemia 
• Percentage time spent at CGM > 63mg/dl to ≤ 180mg/dl (3.5 to ≤ 10.0mmol/l) to quantify 
near optimal target range 
• Area under the curve (AUC) for glucose levels: 
o > 140mg/dl (7.8mmol/l) 
o > 120mg/dl (6.7mmol/l) 
o < 63mg/dl (3.5mmol/l) 
o <50mg/dl (2.8mmol/l) 
• Percentage time CGM worn to quantify compliance 
• Low blood glucose index (LBGI) to quantify the risk of hypoglycaemia 
• Standard deviation (SD) of the rate of change of CGM to quantify the glucose variability 
• Insulin delivered (basal, bolus, and total) to assess insulin needs 
• HbA1c and mean CGM glucose to quantify glucose control 
• Episodes of severe hypoglycaemia requiring assistance (to assess safety) 
• Mild-moderate episodes of hypoglycaemia <63mg/dl or <3.5mmol/l (mild) and <50mg/dl or 
<2.8mmol/l (moderate) from CGM data defined as AUC<63mg/dl or AUC ≤50mg/dl for ≥ 20 
minutes duration (to assess safety) 
• Nocturnal hypoglycaemia (NH): CGM glucose <63mg/dl or <3.5mmol/l (mild) and <50mg/dl 
or <2.8mmol/l (moderate) for ≥ 20 minutes duration between 23:00 and 07:00 hours (to 
assess safety) 
• The frequency and duration of use of closed-loop system as compared to sensor augmented 
pump therapy (to assess feasibility) 
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